Kestra Private Wealth Services LLC Has $859,000 Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Kestra Private Wealth Services LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 47.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,047 shares of the medical device company’s stock after acquiring an additional 3,574 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in DexCom were worth $859,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Versant Capital Management Inc bought a new position in DexCom during the fourth quarter worth $25,000. Riverview Trust Co lifted its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. Heck Capital Advisors LLC bought a new position in shares of DexCom in the fourth quarter valued at $38,000. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom in the third quarter valued at $57,000. Finally, Covestor Ltd lifted its stake in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $84.09 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a 50-day simple moving average of $82.11 and a 200 day simple moving average of $75.19. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market capitalization of $32.85 billion, a PE ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. On average, research analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,342 shares of company stock worth $3,628,069 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent research reports. Sanford C. Bernstein raised their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, JPMorgan Chase & Co. raised their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.